Epidiolex, to treat epilepsy, the first FDA-approved cannabis drug

CBD Epidiolex

For the first time, the US Food and Drug Administration (FDA) has approved a drug made from cannabis.

Epidiolex treats severe forms of childhood epilepsy with CBD. Now that the FDA has validated it, the DEA (Drug Enforcement Administration) will have to requalify this form of cannabis before the drug is available on the market.

CBD, Legalization, FDA, DEA, Epidiolex

Epidiolex: A reclassification needed by the DEA

Indeed, for almost half a century, the DEA has classified cannabis in the Schedule I list of drugs. It is considered the same as heroin and LSD. By comparison, cocaine and methamphetamine are Schedule II drugs. Schedule I drugs are considered to “have no currently accepted medical use and have a high potential for abuse. "

to read :  Italy: legalizing cannabis to boost the national economy

As a result, it is extremely difficult for scientists to research the substance and drug companies are not allowed to use it.

But now, the FDA has approved Epidiolex as medicine. Epidiolex contains cannabidiol, or CBD which is administered as an oil.

According to DEA spokesperson Melvin Patterson, the administration had considered reclassifying CBD and “the FDA's findings on Epidiolex will weigh heavily on the decision-making process. "

However, there is no update on whether the approval will change the timing of the proposed reclassification. The DEA could simply reclassify CBD, but leave cannabis itself in Schedule I.

In order to better understand this problem, this is a federal decision, which therefore applies throughout the territory. The legalization process that we observe in the USA is not federal, but depends on each state. Every decision taken at the federal level is therefore fundamental.

Epidiolex treats two forms of epilepsy, Dravet syndrome and Lennox-Gastaut syndrome, which rarely respond to conventional treatment.

to read :  PPP001 the first pharmaceutical pills approved by Health Canada

GW Pharmaceuticals manufactures this drug. Clinical trials have shown that children taking Epidiolex have almost 40% fewer seizures per month.

A return of research on cannabis

However, this decision concerns "a single compound that comes from the plant and has received approval for two very specific forms of epilepsy," said Daniel Friedman. This associate professor of neurology at the Comprehensive Epilepsy Center at NYU Langone is co-author of a study on Epidiolex to treat Dravet syndrome.

But doctors could prescribe improper use for other forms of epilepsy. Thus the FDA approval could have a domino effect that leads to the reclassification of the DEA. The first consequence: a renaissance of cannabis research in the USA.

Discover the new cannabis-based drugs

Tags : epilepsyLawMedicalResearch
weed master

The author weed master

Weed media broadcaster and communications manager specializing in legal cannabis. Do you know what they say? knowledge is power. Understand the science behind cannabis medicine, while staying up to date with the latest health related research, treatments and products. Stay up to date with the latest news and ideas on legalization, laws, political movements. Discover tips, tricks and how-to guides from the most seasoned growers on the planet as well as the latest research and findings from the scientific community on the medical qualities of cannabis.